

Snow Canyon Therapeutics

SUMMARY

Drug treatments for Osteoarthritis (OA) are symptom modifying drugs that focus on the pain associated with OA. These drugs include nonsteroidal anti-inflammatory drugs (NSAID), steroids, COX-II inhibitors, and opiates. These drugs represent tremendous risk to patients ranging from internal organ damage to addiction.

Snow Canyon Therapeutics is a drug discovery company utilizing a small molecule that stops the progression of arthritis, restores cartilage, and brings arthritic joint back into homeostasis state through regulating redox.

UNMET CLINICAL NEED

'Presently there are no drugs approved that can prevent, stop or even restrain progression of OA' – OARSI



Current standard of care to treat OA is to medically manage pain and inflammation. Invasive surgery is an option for more severe cases. Regardless the treatment modality, cartilage degradation and the health of a joint continue to digress over time.

There is a massive need for a drug that can stop the progression of osteoarthritis, remodel/regrow cartilage, and restore a joint back to a healthy, homeostasis state.

SCT TECHNOLOGY

SCT has discovered that there is more to treating osteoarthritis than suppressing inflammation. By regulating redox, upstream from pro-inflammatory signals we have been able to stop the progression of OA and restore lost and damaged cartilage.

When oxidative stress is regulated, it unlocks gene expression. The cell begins to repair itself.



INTELLECTUAL PROPERTY


- Method of Action of Proprietary Molecules (Patent Application)
- Therapeutic Composition of Matter (Patent Application)

STAGE

Discovery - Preclinical

REGULATORY

Phase 1 in Q3 2024 for OA candidate.



OPPORTUNITY

- Early-stage company with massive potential.
- Providing an unmet need for a disease modifying OA drug.
- Strategic reason to be used on every OA patient.
- Potential for multiple indications, and multiple assets leveraging technology and IP: Type 2 Diabetes, Alzheimer's Disease, Cardiovascular Disease, Psoriasis, Traumatic Brain Injury.

SERIES A - \$10mm

- \$10mm – 24 months
- Used for:
 - IND - enabling studies
 - Phase 1 human trials